• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Safety analysis of co-administering tacrolimus and omeprazole in renal transplant recipients - A review
Biomed Pharmacother. 2023 Aug 22;166:115149. doi: 10.1016/j.biopha.2023.115149. Online ahead of print.ABSTRACTTacrolimus is a calcineurin inhibitor used to prevent rejection in allogenic solid organ transplant recipients, which is metabolized in the liver with cytochrome P450 isoforms 3A4 and 3A5 (CYP3A4, CYP3A5). In turn, proton pump inhibitors (PPIs), such as Omeprazole - a substrate and inhibitor of CYP2C19 and CYP3A4 enzymes - are administered to kidney transplant patients in order to prevent duodenal and gastric ulcer disease, associated with the glucocorticoid treatment. Simultaneous administration of both drugs in r...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - August 24, 2023 Category: Drugs & Pharmacology Authors: Mi łosz Miedziaszczyk Ilona Idasiak-Piechocka Source Type: research

CircFOXN2 alleviates glucocorticoid- and tacrolimus-induced dyslipidemia by reducing FASN mRNA stability by binding to PTBP1 during liver transplantation
CONCLUSION: CircFOXN2 alleviated the dysregulation of lipid metabolism induced by the combination of TAC and Dex by modulating the PTBP1/FASN axis.PMID:37575056 | DOI:10.1152/ajpcell.00462.2022
Source: Am J Physiol Cell Ph... - August 14, 2023 Category: Cytology Authors: Li-Jian Chen Yang Xin Miao-Xian Yuan Chun-Yi Ji Yu-Ming Peng Qiang Yin Source Type: research

Physiologically based pharmacokinetic model combined with reverse dose method to study the nephrotoxic tolerance dose of tacrolimus
This study aimed to explore the tolerated dose of nephrotoxicity of TAC in individuals with different CYP3A5 genotypes and liver conditions. We established a human whole-body physiological pharmacokinetic (WB-PBPK) model and validated it using data from previous clinical studies. Following the injection of 1 mg/kg TAC into the tail veins of male rats, we developed a rat PBPK model utilizing the drug concentration-time curve obtained by LC-MS/MS. Next, we converted the established rat PBPK model into the human kidney PBPK model. To establish renal concentrations, the BMCL5 of the in vitro CCK-8 toxicity response curve (drug...
Source: Archives of Toxicology - August 12, 2023 Category: Toxicology Authors: Limin Cai Meng Ke Han Wang Wanhong Wu Rongfang Lin Pinfang Huang Cuihong Lin Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20